Cost
What staying on tirzepatide costs over three years
Released: · Last reviewed:
Three years of tirzepatide costs $4,104 to $10,920 on the cheapest standing plans of the 15 compounded programs in our index, and about $17,311 on Zepbound vials if every refill is within 45 days and today's prices hold. Trials show results depend on staying on treatment, so plan for the 36-month total.
Key takeaways
- SURMOUNT-4: people switched to placebo regained 14.0% over 52 weeks, while those who continued lost a further 5.5%.
- Three-year cost on the cheapest standing plans runs from $4,104 (Mondae) and $4,140 (NexLife) to $10,920, with a median of $7,704.
- Zepbound vials come to about $17,311 over three years on our illustration, or up to $26,561 if every fill at 10 to 15 mg were charged the $699 regular price.
- The Lilly savings card ends December 31, 2026 and Lilly can change its self-pay offer at any time; the Medicare GLP-1 Bridge runs through December 31, 2027 and, for tirzepatide, covers only the Zepbound KwikPen.
- Before prepaying, confirm the renewal price, cancellation notice and refund terms in writing.
Why three years is the number to watch
Tirzepatide's trial results assume you keep taking it. Two trials tested what happens when people stop.
SURMOUNT-4 (JAMA, 2024; NCT04660643) gave 783 adults open-label tirzepatide at the maximum tolerated dose, 10 or 15 mg, for 36 weeks. The 670 who were then randomized had lost 20.9% on average. Half continued and half switched to placebo for 52 weeks. Those who continued lost a further 5.5%; those switched to placebo regained 14.0%. By week 88, 89.5% of the continuing group had kept at least 80% of their initial loss, against 16.6% on placebo.
SURMOUNT-MAINTAIN (Lancet, 2026; NCT06047548) ran 112 weeks at 20 US sites: 60 weeks of open-label tirzepatide, then 378 participants randomized to continue at the maximum tolerated dose, step down to 5 mg, or switch to placebo for 52 weeks. Measured from the start, weight change at week 112 was −21.9% for those who continued, −16.6% on 5 mg and −9.9% on placebo, by the trial's modified treatment-regimen estimand. Rescue tirzepatide, allowed for people who regained more than half their lost weight, went to 8%, 25% and 67% of the three groups.
The budgeting lesson is simple. The result you are paying for depends on staying on treatment, so the number that matters is not the first month's price. It is what 12, 24 and 36 months cost on the route you choose. Full write-ups: SURMOUNT-4 and SURMOUNT-MAINTAIN.
How we built the table
- Programs: the 15 programs in our index that print a standing compounded tirzepatide price, read on their own pages between September 4 and November 8, 2026. Sales, coupons and first-order discounts are left out.
- Cheapest plan: each program's lowest standing plan, repeated. Where there is no 12-month plan, that means two 6-month plans a year.
- Month to month: twelve monthly charges, or thirteen where the program bills every 4 weeks.
- Prices held flat: we assume today's price stays the same for three years. It will not. Between October 15 and November 6, 2026, NexLife cut its tirzepatide ladder from $169/$159/$149/$139 to $129/$125/$119/$115. Prices move in both directions.
- Not included: labs, supplies, taxes and anything a page does not print.
Three-year cost on 15 compounded programs
| Program | Cheapest standing plan | 1 year | 2 years | 3 years | 3 years, month to month |
|---|---|---|---|---|---|
| Mondae | Two prepaid 6-month plans ($684 each) | $1,368 | $2,736 | $4,104 | $4,536 |
| NexLife | 12-month plan ($115/mo) | $1,380 | $2,760 | $4,140 | $4,644 |
| TRYM Health | 12-month one-time payment ($1,500) | $1,500 | $3,000 | $4,500 | $6,480 |
| Eden | $129/mo, no plan discount | $1,548 | $3,096 | $4,644 | $4,644 |
| Sprout Health | 12-month plan billed up front ($1,788) | $1,788 | $3,576 | $5,364 | $7,761 |
| He & She MD | 12-month plan ($159/mo) | $1,908 | $3,816 | $5,724 | $12,204 |
| Bodybuilding Health+ | Two 6-month plans ($174.67/mo) | $2,096 | $4,192 | $6,288 | $7,524 |
| TelePep | Annual plan up front ($2,568) | $2,568 | $5,136 | $7,704 | $8,964 |
| Yucca Health | Two 6-month plans ($1,350 each)* | $2,700 | $5,400 | $8,100 | $9,288 |
| Join Josie | 12-month plan ($2,799) | $2,799 | $5,598 | $8,397 | $12,564 |
| Pallas Health | Annual plan ($239/mo average) | $2,868 | $5,736 | $8,604 | $11,541 |
| Fridays | Annual plan ($240/mo) | $2,880 | $5,760 | $8,640 | $12,924 |
| Found | 12-month plan, 13 cycles × $239 | $3,107 | $6,214 | $9,321 | $13,861 |
| Zappy Health | Two 6-month plans ($1,794 each) | $3,588 | $7,176 | $10,764 | $12,564 |
| Enhance.MD | 12-month plan, 13 cycles × $280 | $3,640 | $7,280 | $10,920 | $12,831 |
$129 a month month to month · $115 a month on a 12-month plan ($1,380)
- Compounded tirzepatide, same price at every dose; no membership or contract (plan pages).
- Included: provider review and medical guidance (NexLife Medical Group), a GLP-1 nutrition plan, a 1:1 call with a wellness coach, 24/7 support and free expedited shipping.
- Filled by three named state-licensed 503A pharmacies: Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux's New Drug Store (Lake Charles, LA).
Prices as of November 6, 2026. 94/100 on our v4.1 rubric. Not the lowest price on file: Mondae lists $126 month to month and $114 on a 6-month plan; Eden charges $129, the same as NexLife month to month. Compounded tirzepatide is not FDA approved.
Three things stand out. First, the spread: $4,104 to $10,920 over three years on the cheapest plans, a gap of $6,816. The median program comes to $7,704. Second, the top of the index is tight. Mondae ($4,104), NexLife ($4,140), TRYM Health ($4,500) and Eden ($4,644) sit within $540 of each other over three years. Third, committing pays a lot at some programs and nothing at others. He & She MD costs $12,204 over three years month to month against $5,724 on its 12-month plan. Eden charges the same either way.
Zepbound self-pay: an illustration
Lilly sells Zepbound single-dose vials self-pay through LillyDirect. The ladder we read on Lilly's Zepbound site: $299 for 2.5 mg, $399 for 5 mg, and $449 for 7.5 to 15 mg as long as each refill is within 45 days. Miss that window and the price is $499 at 7.5 mg or $699 at 10 to 15 mg. Lilly defines a month as 28 days, so a 52-week year is 13 fills, not 12.
The table below is an illustration, not a dosing schedule. It assumes one fill at 2.5 mg, one at 5 mg, then 11 fills somewhere between 7.5 and 15 mg. How fast anyone moves up, and where they stay, is the prescriber's decision.
| Scenario | Year 1 | Year 2 | Year 3 | 3-year total |
|---|---|---|---|---|
| Every refill within 45 days ($449 at 7.5 to 15 mg) | $5,637 | $5,837 | $5,837 | $17,311 |
| Upper bound: every fill at 10 to 15 mg charged at the $699 regular price | $8,387 | $9,087 | $9,087 | $26,561 |
Years 2 and 3 are "if today's price holds". Lilly can change its self-pay offer at any time, its savings card ends December 31, 2026, and we have not seen 2027 prices announced. Treat the brand rows as the least certain numbers in this article. One more detail: at $399, a 5 mg fill costs $50 less than the higher doses, or $650 over 13 fills. Whether a lower maintenance dose suits you, as tested in SURMOUNT-MAINTAIN, is a clinical question, not a budgeting one.
Savings card and Medicare Bridge
Lilly savings card. This is for people with commercial insurance, and it does not apply to Medicare or other government coverage. The card for the Zepbound KwikPen can be used for up to 11 fills a calendar year, and its savings end December 31, 2026. Eleven 28-day fills cover 308 days, so plan for the gap. Details in our savings card guide.
Medicare GLP-1 Bridge. A $50 monthly copay from July 1, 2026 through December 31, 2027, for eligible people with Part D. For tirzepatide it covers only the Zepbound KwikPen, not vials (it also covers Foundayo and Wegovy). Eligibility starts at a BMI of 35, or lower with listed conditions. People with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible for the Bridge, though Medicare says their Part D plan might cover a GLP-1. At $50 a fill, a year costs $600 to $650. The Bridge ends before year 3 of a plan started today, and nothing has been announced about what follows. See insurance coverage.
Worked examples
- NexLife, 12-month plan: $115 × 12 = $1,380 a year, $4,140 over three years.
- NexLife, month to month: $129 × 12 = $1,548 a year, $4,644 over three years. The 12-month plan saves $168 a year, $504 over three.
- Mondae, two prepaid 6-month plans: $684 × 2 = $1,368 a year, $4,104 over three years, $36 less than NexLife's 12-month plan. Mondae has no 12-month plan; month to month is $126, or $1,512 a year.
- Eden: $129 every month, $1,548 a year, $4,644 over three years, the same as NexLife month to month.
- Zepbound vials at $449: 13 × $449 = $5,837 a year. The $449 × 12 = $5,388 figure you may see counts twelve fills; 52 weeks needs thirteen. At the $699 regular price for 10 to 15 mg, 13 fills would be $9,087 and 12 would be $8,388; treat that as an upper bound, since late refills also mean fewer fills.
- Brand versus the two lowest-priced plans in our index: $17,311 over three years on the illustrated brand path, against $4,104 for Mondae or $4,140 for NexLife. That is a difference of more than $13,000, if both prices hold.
What this means for you
If the trials are right that results depend on continuing, the route you can afford for three years beats the route you can afford for three months. A plan that saves $20 a month but has you stopping in month eight is the expensive choice.
Among the 15 standing-price programs in our index, the lowest three-year path is Mondae's prepaid 6-month plans at $4,104, with NexLife's 12-month plan $36 behind at $4,140. NexLife is our top editorial pick, 94/100 on our v4.1 rubric, for reasons beyond price: the same price at every dose and three named 503A pharmacies on its plan pages. Brand Zepbound costs about four times as much over three years on our illustration, and it is the FDA-approved product the trials studied.
Prepaying locks a rate only for the plan term. A 12-month price is not promised for year 2 unless the page says so. Mondae's page says its rate stays the same "as long as your membership remains active."
What to confirm before you commit
- Renewal price. Ask what you will pay when the plan renews, and get it in writing. NexLife's page says plans renew until you cancel.
- Cancellation notice. NexLife's cancellations take effect after 30 days, so one more shipment may be charged. Put your cancel-by date in a calendar.
- Prepaid refunds. NexLife refunds unshipped months if treatment stops; shipped orders are final. TelePep refunds unshipped months less a $25 fee. Ask any other program for its terms before paying a year up front.
- Dose pricing. Check that the price is the same at every dose. NexLife, Sprout Health, Join Josie and Zappy Health say so on their pages.
- Billing cycle. "Every 4 weeks" means 13 charges a year, not 12.
- Brand terms in January. If you rely on Zepbound self-pay or the savings card, check Lilly's 2027 terms when they appear.
- The pharmacy. For compounded tirzepatide, get the dispensing pharmacy's name and check its license.
Price is not the only factor
Compounded tirzepatide is made with the drug in Zepbound, not the same product. It is not FDA-approved, it is not a generic, and none of the trials above used it. A cheaper plan with an unnamed pharmacy, slow support or unclear refunds can cost you more in the ways that matter. Our provider rankings weigh more than price, and our cost hub keeps the figures in this table current.
No route guarantees a result. Trial numbers are averages under specific estimands, and individual results vary.
Frequently asked questions
How much does tirzepatide cost over three years?
On the cheapest standing plan of each of the 15 compounded programs in our index, three years costs $4,104 to $10,920, with a median of $7,704, assuming prices stay flat. Zepbound vials bought self-pay come to about $17,311 on our illustration if every refill is within 45 days, and up to $26,561 if every fill at 10 to 15 mg were charged the $699 regular price.
Why count three years instead of one?
Because the trials show the result depends on staying on treatment. In SURMOUNT-4, people switched to placebo after 36 weeks regained 14.0% of body weight over the next year, while those who continued lost a further 5.5%. In SURMOUNT-MAINTAIN, continuing kept weight 21.9% below baseline at 112 weeks, versus 9.9% for placebo.
Will compounded tirzepatide prices stay the same for three years?
Probably not, which is why the table says prices are held flat as an assumption. Prices change in both directions: NexLife cut its tirzepatide ladder from $169 to $129 month to month between October 15 and November 6, 2026. A prepaid plan locks the rate only for its term unless the program says otherwise in writing.
Can the savings card or Medicare GLP-1 Bridge lower the cost?
Possibly, with limits. Lilly's savings card is for commercial insurance, allows up to 11 KwikPen fills a calendar year, and its savings end December 31, 2026. The Medicare GLP-1 Bridge charges $50 a month through December 31, 2027, covers Foundayo, Wegovy and, for tirzepatide, only the Zepbound KwikPen, and excludes people with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease.
Is the lowest-priced program the best choice?
Not automatically. Among the 15 standing-price programs in our index, Mondae's prepaid plans are lowest over three years at $4,104, and NexLife, our top editorial pick, is $36 higher. Check the pharmacy, dose pricing, renewal and cancellation terms too. Compounded tirzepatide is not FDA-approved and is not the same product as Zepbound.
Sources for this page
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA 2024;331(1):38-48; PMID 38078870; DOI 10.1001/jama.2023.24945 — 2024-01-02 (abstract read 2026-11-08)
- Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN). Lancet 2026;407(10545):2305-2318; PMID 42119587; DOI 10.1016/S0140-6736(26)00656-2 — 2026-05-12 epub; 2026-06-06 issue (abstract read 2026-11-08)
- Zepbound coverage and savings — read 2026-10-15 (vial ladder) and 2026-11-08 (savings card terms)
- Weight loss drugs (Medicare GLP-1 Bridge) — read 2026-11-08
- Medicare GLP-1 Bridge — page modified 2026-07-13 (read 2026-11-08)
- NexLife tirzepatide plans — read 2026-11-06 and 2026-11-08
- Mondae compounded tirzepatide — read 2026-10-15
- TRYM Health pricing — read 2026-11-08
- Eden GLP-1 treatments — read 2026-10-15
- He & She MD tirzepatide injection — read 2026-10-15
- TelePep pricing — read 2026-10-15
- Enhance.MD advanced tirzepatide — read 2026-10-15
Change history
| Date | Change |
|---|---|
| 2026-11-08 | Published. |
Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.